{"disease":{"id":"nafld-nash-combination-therapy-with-dgat2i","name":"nafld nash combination therapy with dgat2i"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"pf-05221304","indication_name":"NAFLD/NASH (combination therapy with DGAT2i)","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-05221304","generic_name":"pf-05221304","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Acetyl-CoA carboxylase (ACC1 and ACC2)","drug_class":"Acetyl-CoA carboxylase inhibitor","quality_score":27,"revenue":null,"mechanism":"Selective inhibitor of acetyl-CoA carboxylase (ACC1/ACC2) that reduces hepatic lipogenesis and promotes fatty acid oxidation."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}